Exploring gut metabolites and heart function in heart attack patients
the Association of Intestinal Microbial Metabolites and Cardiac Function in Acute Myocardial Infarction
Peking University Third Hospital · NCT04955054
This study is looking at how gut bacteria and their products might affect heart function in people who have had a heart attack.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT04955054 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between intestinal microbial metabolites, specifically bile acids and short chain fatty acids, and cardiac function in patients who have experienced an acute myocardial infarction (AMI). By analyzing these metabolites, the study aims to understand their role in the pathophysiology of cardiovascular diseases and their potential as intervention targets. The research will involve patients aged 18-85 who have undergone coronary angiography and consented to participate. The findings could provide insights into how gut health impacts heart health, particularly in the context of AMI.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-85 who have experienced an acute myocardial infarction and have undergone coronary angiography.
Not a fit: Patients with chronic heart failure, recent acute infections, or significant liver or kidney dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies targeting gut metabolites to improve cardiac function in heart attack patients.
How similar studies have performed: While there is emerging evidence linking gut metabolites to cardiovascular health, this specific association has not been extensively studied, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The patient, aged 18-85 years, had undergone coronary angiography and agreed to be enrolled and signed the informed consent. AMI : according to ST segment elevation myocardial infarction diagnostic criteria. UAP: 1. typical chest pain symptoms; 2. negative in markers of myocardial injury; 3. The stenosis of main coronary artery or its main branches is more than 50% Control: 1. atypical chest pain symptoms 2. negative in markers of myocardial injury; 3. The stenosis of main coronary artery and its main branches is less than 50% Exclusion Criteria: 1. Acute infection or application of antibiotics in the past 3 months; 2. Chronic heart failure; 3. History of inflammatory or absorptive bowel disease and bowel resection; 4. Acute, chronic liver disease or other reasons lead to abnormal liver function (transaminase is more than 5 times of normal value); 5. Renal insufficiency (serum creatinine \> 220μml/L or creatinine clearance rate \< 30 ml/min); 6. Malignant tumor; 7. Autoimmune diseases; 8. Uninformed patients
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Myocardial Infarction, bile acids, short chain fatty acid, cardiac function